INTRODUCTION {#s1}
============

Colorectal cancer (CRC) is a major global healthcare problem, including in Japan; the mortality rate of patients with CRC is twice that of 20 years ago. In Japan, this malignancy has become the third leading cause of cancer death in males and the leading cause of cancer death in females (<http://www.mhlw.go.jp/english/>) \[[@R1]\]. The incidence of CRC is still high in highly industrialized countries, and the number of CRC cases has increased in many developing countries that have undergone rapid economic transformations and adopted a Western lifestyle \[[@R2]\].

Because CRC usually arises from colorectal adenoma, the early detection and removal of colorectal adenoma by endoscopy can help avoid CRC-related death \[[@R3]\]. The prevention of colorectal adenoma development by determining the environmental risk factors and identifying high-risk patients might also be significant in reducing the rate of death caused by CRC. Accumulating evidence shows that a Western diet (imbalanced diet), sedentary lifestyle, alcohol consumption, tobacco use, lack of physical activity, sleep deprivation and obesity are significant risk factors for CRC \[[@R4]--[@R6]\]. Among these risk factors, obesity and its related medical problems, especially type 2 diabetes mellitus (DM), are well known to play a critical role in the development of CRC.

Several pathophysiological mechanisms have been shown to be involved in the correlation between type 2 DM and colorectal carcinogenesis \[[@R7]\], including the occurrence of insulin resistance and the induction of chronic inflammation \[[@R8], [@R9]\]. The effects of dietary- and lifestyle-related risk factors on CRC are suggested to be mediated through hyperinsulinemia \[[@R4]\], which occurs in most type 2 DM patients \[[@R10], [@R11]\]. Exogenous insulin injection stimulates the growth of CRC precursors in animal models \[[@R12], [@R13]\]. A recent prospective study revealed a significant relationship between the development of CRC and insulin use in patients with type 2 DM \[[@R14]\]. A systematic review and meta-analysis also showed that insulin use is a risk factor for CRC \[[@R15]\].

It is well-reported that several dietary factors, such as vitamins, green tea catechin and certain kinds of vegetables and fruits, can exert chemopreventive properties against colorectal neoplasia \[[@R16]--[@R20]\]. In a preliminary human trial, supplementation with green tea catechin, which can suppress diabetes-related colorectal carcinogenesis in mice by improving hyperinsulinemia \[[@R21]\], successfully prevented the development of colorectal adenomas \[[@R22]\]. Furthermore, several preclinical trials have shown that conventional anti-diabetic medications may modify the risk of some cancers, including CRC \[[@R8], [@R23], [@R24]\]. For instance, metformin, an anti-diabetic agent, is expected to prevent the development of colorectal neoplasms \[[@R25]\]. In addition to anti-diabetic drugs, several studies have revealed the correlation between a decreased risk of colorectal tumorigenesis and current medications for lifestyle-related diseases, such as hypertension and dyslipidemia \[[@R26]--[@R29]\]. These reports suggest that the evaluation of medications might be useful for identifying subjects at high risk for developing colorectal neoplasia.

In the present study, we investigated the factors that influence the incidence of CRC in patients with type 2 DM. These factors included the patient' characteristics, medical history, family history, habits (smoking and alcohol intake) and medications associated with lifestyle-related disease, such as type 2 DM, hypertension, dyslipidemia and ischemic disease due to atherosclerosis. These factors are commonly confirmed with a medical interview and can therefore useful in a clinical setting. The purpose of this study was to identify diabetic patients at a higher or lower risk for CRC development with a focus on the factors described above.

RESULTS {#s2}
=======

Patient flowchart and characteristics of patients with or without type 2 DM {#s2_1}
---------------------------------------------------------------------------

The patient flowchart is shown in Figure [1](#F1){ref-type="fig"}. Among the 1176 patients who were enrolled in this study, the 170 who met the diagnostic criteria of the Japanese Diabetes Society \[[@R30]\] or who were prescribed anti-diabetic medications were diagnosed with type 2 DM. Among them, two cases were excluded because of the presence of UC. Thus, 168 diabetic patients were ultimately evaluated. Colorectal neoplasia was detected by TCS in 70 (41.7%) of these type 2 DM patients. Colorectal neoplasia was detected in 345 of the 1006 (34.3%) non-diabetic patients in this study. As shown in Table [1](#T1){ref-type="table"}, the statistical analysis demonstrated significant differences between the diabetic and non-diabetic patients with regard to the mean age (*p* \< 0.001), the proportion of patients with a higher BMI (≥ 25, *p* \< 0.001) and complication with hypertension (*p* \< 0.001) and dyslipidemia (*p* = 0.002). The incidence of colorectal neoplasia tended to be higher in diabetic patients than in non-diabetic patients; however, the difference did not reach statistical significance (*p* = 0.064).

![Patient flowchart\
DM: diabetes mellitus. UC: ulcerative colitis.](oncotarget-08-97862-g001){#F1}

###### Baseline characteristics of the patients with or without type 2 DM

                                      DM (*n* = 168)     non DM (*n* = 1006)
  ----------------------------------- ------------------ ---------------------
  Age, mean ± SD                      71.6 ± 10.1 ^\*^   65.2 ± 15.4
  Gender, male                        111 (65.3%)        585 (58.4%)
  BMI (≥ 25 kg/m^2^)                  55 (34.4%) ^\*^    157 (16.8%)
  Hypertension                        98 (58.3%) ^\*^    371 (36.9%)
  Dyslipidemia                        60 (35.7%) ^\*^    238 (23.7%)
  Alcohol use                         57 (33.9%)         351 (31.3%)
  Smoking                             39 (23.2%)         224 (22.3%)
  Incidence of colorectal neoplasia   70 (41.7%)         345 (34.3%)
  HbA1c (%), mean ± SD                7.3 ± 2.2          N/A

DM: diabetes mellitus, BMI: body mass index, SD: standard deviation.

^\*^:Significant difference between the groups (*p* \< 0.05).

A comparison of the characteristics between type 2 diabetic patients with or without colorectal neoplasia {#s2_2}
---------------------------------------------------------------------------------------------------------

Table [2](#T2){ref-type="table"} shows the comparison of the clinical characteristics between diabetic patients with or without colorectal neoplasia detected by TCS. There were no significant differences in the median age, the BMI, the HbA1c values or the rate of positive FIT between the tumor group (*n* = 70) and the non-tumor group (*n* = 98). The proportion of men in the tumor group was significantly higher than in the non-tumor group (77.1% vs. 56.1%, *p* = 0.005). There were no significant differences between the two groups with regard to the rates of complication with hypertension and dyslipidemia, alcohol consumption or smoking.

###### Comparison of the clinical characteristics in patients with or without colorectal neoplasia

                           Presence of colorectal neoplasia                     
  ------------------------ ---------------------------------- ----------------- -------------
  Age (years), mean ± SD   72.2 ± 9.3                         71.1 ± 10.7       *p* = 0.455
  Gender, male (%)         77.1 (54)                          56.1 (55)         *p* = 0.005
  BMI (≥ 25 kg/m^2^)       29.4 (20)                          35.7 (34)         *p* = 0.420
  HbA1c, mean ± SD         7.02 ± 1.6 (18)                    7.50 ± 2.4 (37)   *p* = 0.455
  Positive of FIT (%)      63.7 (14)                          53.3 (16)         *p* = 0.458
  Complications                                                                 
   Hypertension            58.6 (41)                          57.1 (56)         *p* = 0.853
   Dyslipidemia            37.1 (26)                          34.7 (34)         *p* = 0.744
  Habits                                                                        
   Alcohol use             37.1 (26)                          30.6 (30)         *p* = 0.376
   Smoking                 30 (21)                            18.4 (18)         *p* = 0.078
  Medications                                                                   
   LDA                     8.6 (6)                            18.4 (18)         *p* = 0.079
   ADPR                    4.3 (3)                            13.3 (13)         *p* = 0.063
   PDEIII-I                1.4 (1)                            4.1 (4)           *p* = 0.403
   Anti-coagulant          8.6 (6)                            2.0 (2)           *p* = 0.068
   Sulfonylureas           28.6 (20)                          23.5 (23)         *p* = 0.455
   Biguanide               18.6 (13)                          20.4 (20)         *p* = 0.768
   Tiazoridine             17.1 (12)                          10.2 (10)         *p* = 0.189
   α-GI                    12.9 (9)                           27.6 (27)         *p* = 0.023
   Glinide                 4.3 (3)                            1.0 (1)           *p* = 0.309
   DPP4                    48.6 (34)                          44.9 (44)         *p* = 0.638
   Insulin                 7.1 (5)                            9.2 (9)           *p* = 0.780
   ACEI                    4.3 (3)                            6.1 (6)           *p* = 0.736
   ARB                     37.1 (26)                          32.7 (32)         *p* = 0.546
   Ca-blocker              42.9 (30)                          34.7 (34)         *p* = 0.283
   β-blocker               5.7 (4)                            7.1 (7)           *p* = 0.764
   α-blocker               8.6 (6)                            9.2 (9)           *p* = 0.891
   Statin                  35.7 (25)                          19.4 (19)         *p* = 0.018
   Fibrate                 2.9 (2)                            4.1 (4)           *p* = 0.673
   NSAIDs                  20.0 (14)                          20.4 (20)         *p* = 0.948

DM: diabetes mellitus, SD: standard deviation, FIT: fecal immunochemical test, LDA: Low dose aspirin, ADPR: adenosine diphosphate receptor I agonist, PDEIII-I: phosphodiesterase III inhibitor, α-GI: α-glucosidase inhibitor, DPP4: dipeptidyl peptidase-4 inhibitor, ACEI: angiotensin coenzyme inhibitor, ARB: angiotensin-2 receptor blocker, Ca-blocker: calcium blocker, NSAIDs: non-steroidal anti-inflammatory drugs.

Among the drugs that were used for the treatment of lifestyle-related diseases, α-GIs (miglitol/voglibose/acarbose: 14/20/2) and statins (rosuvastatin/atorvastatin/pravastatin/pitavastatin/simvastatin/fluvastatin: 20/18/2/2/1/1) were found to be significantly associated with the incidence of colorectal neoplasia. The ratio of the patients who were taking α-GIs in the tumor group was lower than in the non-tumor group (12.9% vs. 27.6%; *p* = 0.023), but the ratio of the patients who were taking statins in the tumor group was significantly higher than in the non-tumor group (35.7% vs. 19.4%; *p* = 0.018). All patients treated with α-GIs (*n* = 36) or statins (*n* = 44) took normal doses of these agents approved as a legitimate treatment in Japan.

Predictors associated with colorectal neoplasia in patients with type 2 DM {#s2_3}
--------------------------------------------------------------------------

In order to identify the predictors of colorectal neoplasia in patients with type 2 DM, univariate and multivariate analyses were performed with a focus on the candidate variables. In addition to three variables (male gender, α-GI use, and statin use) based on the results shown in Table [2](#T2){ref-type="table"}, we selected 11 variables (BMI, hypertension, dyslipidemia, alcohol use, smoking, Biguanide use, ACEI use, ARB use, β-blocker use, LDA use, and NSAIDs use), all of which are reported to increase or decrease the risk of CRC \[[@R6], [@R25], [@R31]--[@R38]\], for these analyses.

The univariate analysis revealed that male gender (odds ratio \[OR\] = 2.64, 95% confidence interval \[CI\] = 1.33--5.24, *p* = 0.005) and taking statins (OR = 2.31, 95% CI = 1.15--4.65, *p* = 0.018) were independent risk factors for colorectal neoplasia. In contrast, taking α-GIs (OR = 0.39, 95% CI = 0.17--0.89, *p* = 0.023) was independently associated with a decreased risk of colorectal neoplasia. The multivariate analysis also revealed that male gender (OR = 4.04, 95% CI = 1.67--10.37, *p* = 0.002) and taking statins (OR = 4.59, 95% CI = 1.69--13.43, *p* = 0.003) were significantly associated with an increased risk, while taking α-GIs (OR = 0.35, 95% CI = 0.13--0.87, *p* = 0.023) and LDA (OR = 0.32, 95% CI = 0.10--0.95, *p* = 0.040) were significantly associated with a decreased risk of colorectal neoplasia in type 2 DM patients (Table [3](#T3){ref-type="table"}).

###### Predictors of colorectal neoplasia in patients with type 2 DM

                   Univariate analysis   Multivariate analysis                        
  ---------------- --------------------- ----------------------- -------------------- -------
  Age                                                                                 
   \< 70 years     1                                             1                    
   ≥ 70 years      1.18 (0.62--2.26)     0.604                   1.70 (0.78--3.82)    0.186
  BMI                                                                                 
   \< 25 kg/m^2^   1                                             1                    
   ≥ 25 kg/m^2^    0.76 (0.39--1.48)     0.420                   0.79 (0.35--1.75)    0.559
  Gender                                                                              
   female          1                                             1                    
   male            2.64 (1.33--5.24)     0.005                   4.04 (1.67--10.37)   0.002
  Complications                                                                       
   hypertension    1.06 (0.57--1.93)     0.853                   1.37 (0.55--3.44)    0.494
   dyslipidemia    1.11 (0.59--2.11)     0.744                   0.69 (0.26--1.76)    0.443
  Habits                                                                              
   alcohol use     1.34 (0.70--2.56)     0.376                   0.79 (0.33--1.86)    0.582
   smoking         1.90 (0.92--3.93)     0.078                   1.81 (0.74--4.50)    0.193
  Medications                                                                         
   α-GI            0.39 (0.17--0.89)     0.023                   0.35 (0.13--0.87)    0.023
   Biguanide       0.89 (0.41--1.94)     0.768                   0.70 (0.26--1.84)    0.479
   Statin          2.31 (1.15--4.65)     0.018                   4.59 (1.69--13.43)   0.003
   ACEI            0.69 (0.17--2.84)     0.736                   0.63 (0.11--2.88)    0.560
   ARB             1.22 (0.64--2.32)     0.546                   1.29 (0.52--3.26)    0.582
   β-blocker       0.79 (0.22--2.80)     0.764                   0.49 (0.10--2.10)    0.340
   LDA             0.42 (0.16--1.11)     0.079                   0.32 (0.10--0.95)    0.040
   NSAIDs          0.98 (0.45--2.09)     0.948                   0.89 (0.34--2.25)    0.806

OR: odds ratio, 95% CI: 95% confidence interval, BMI: body mass index, α-GI: α-glucosidase I inhibitor, ACEI: angiotensin coenzyme inhibitor, ARB: angiotensin receptor blocker, LDA: low-dose aspirin, NSAIDs: non-steroidal anti-inflammatory drugs.

DISCUSSION {#s3}
==========

Several epidemiological studies have revealed that complications with lifestyle-related diseases, especially type 2 DM, and medications for such diseases are associated with the risk of colorectal tumorigenesis \[[@R7]\]. Among the conventional anti-diabetic medications, the use of metformin by diabetic patients may be associated with a lower risk of CRC \[[@R39], [@R40]\]. Thiazolidine has also been suggested to exert chemopreventive effects against cancer \[[@R41]\]. In contrast, sulfonylureas, which stimulate insulin secretion, and insulin itself may stimulate cell proliferation and inhibit apoptosis, which may contribute to tumorigenesis \[[@R42]\]. The results of the present study showed the first evidence that taking α-GI may reduce the risk of colorectal tumorigenesis in Japanese type 2 diabetic patients. In a recent nationwide, population-based cohort study in Taiwan, taking acarbose, an α-GI, was found to significantly reduce the risk of CRC development in diabetic patients in a dose-dependent manner \[[@R43]\]. The results were consistent with those of the present study. In addition, the present results showing that taking LDA reduced the incidence of colorectal neoplasia are also consistent with those of previous studies \[[@R44]\].

Several epidemiological and fundamental medical studies have revealed that type 2 DM is as an independent risk factor for CRC \[[@R45]\]. Among the pathophysiological conditions induced by type 2 DM, an increased insulin level is critically involved in colorectal tumorigenesis \[[@R11], [@R46]\]. These findings also suggest that targeting insulin resistance as well as hyperinsulinemia might be effective strategies for suppressing CRC development \[[@R21], [@R47]\]. The use of α-GI, which prevents a rapid postprandial increase in the blood glucose level by delaying carbohydrate absorption in the small intestine \[[@R48]\], is reported to improve hyperinsulinemia \[[@R49]\]. This might be a key mechanism underlying its suppression of colorectal neoplasia. A clinical study showed that α-GI therapy reduces the bowel transit time of stool in diabetic patients \[[@R50]\], which also explains the protective effect of α-GI against colorectal tumorigenesis because the long-term exposure to bile acids due to delayed stool transit plays a role in CRC development \[[@R51]\]. α-GI is reported to increase the levels of butyrate, which is associated with the inhibited growth of the transformed cells in the colorectal mucosa \[[@R52]\]. The antineoplastic effects of α-GI, which include the prevention of angiogenesis and the inhibition of tumor growth, have been reported in basic studies \[[@R23]\]. These findings suggest that α-GI may both directly and indirectly suppress colorectal tumorigenesis.

Statins, which are widely used as lipid-lowering drugs, have been shown to safely and effectively reduce mortality from cardiovascular disease \[[@R53]\]. They have also demonstrated antineoplastic properties in various organs, including the colorectum, in experimental studies \[[@R28], [@R54]\]. Epidemiological studies have suggested the chemopreventive effects of statins against CRC \[[@R55]\]; however, taking statins was found to be an independent risk factor for colorectal neoplasia in the present study. This result might be due to the limitations of the present study. First, this small-size case-control study did not take the administration period of significant drugs, including statins and α-GIs, into account. Second, the serum levels of cholesterol and its density before and after statin treatment were not evaluated. These evaluations are important, as high serum concentrations of high-density lipoprotein cholesterol are associated with a decreased risk of colon cancer \[[@R33]\], but a rapid reduction in cholesterol might increase the risk of colorectal tumorigenesis \[[@R56]\]. The evaluation of the types of statins (i.e. lipophilic or hydrophilic statins) that are prescribed to patients is also significant because lipid solubility is associated with the chemopreventive effects of these agents \[[@R57]\]. Future large-scale prospective studies should be conducted to clarify these limitations.

Finally, it should be emphasized that the early detection of colorectal neoplasia and their prevention are critical to reducing CRC-related mortality \[[@R5], [@R58]\]. Thus, subjects who have several risk factors for CRC should undergo careful examinations such as TCS \[[@R6]\]. The results of this study may suggest that male diabetic patients taking statins in particular should undergo TCS. Furthermore, intervention trials to clarify the chemopreventive effects of α-GIs on colorectal tumorigenesis seem to be particularly important, as targeting the metabolic alterations associated with type 2 DM, such as hyperinsulinemia, can be an effective strategy for preventing the development of CRC in patients with lifestyle-related diseases \[[@R8]\].

In conclusion, taking α-GIs and/or LDA may be an effective way of suppressing colorectal tumorigenesis in patients with type 2 DM. In contrast, male gender and taking statins may be associated with an increased risk of developing CRC in diabetic patients, and these individuals may require careful surveillance.

MATERIALS AND METHODS {#s4}
=====================

Subjects and study protocol {#s4_1}
---------------------------

A total of 1176 patients who underwent total colonoscopy (TCS) at Gihoku Kosei Hospital for the first time from August 2012 to June 2014 were enrolled in this retrospective study. These patients were divided by complication with type 2 DM. The exclusion criterion was the presence of ulcerative colitis (UC), as patients diagnosed with this disease are known to be a high-risk group for CRC \[[@R59]\].

The subjects were carefully interviewed prior to TCS to determine their characteristics (age, gender, body mass index \[BMI\], HbA1c values and the result of fecal immunochemical test), habits (alcohol consumption and smoking), complications with lifestyle-related diseases (hypertension and dyslipidemia) and prescriptions for these diseases (low-dose aspirin \[LDA\], adenosine diphosphate receptor I agonist \[ADPR\], phosphodiesterase III inhibitor \[PDEIII-I\], anti-coagulant, sulfonylureas, tiazoridine, α-glucosidase inhibitor \[α-GI\], glinide, dipeptidyl peptidase-4 inhibitor \[DPP4\], insulin, angiotensin coenzyme inhibitor \[ACEI\], angiotensin-2 receptor blocker \[ARB\], calcium blocker \[Ca-blocker\], β-blocker, α-blocker, statin, fibrate and non-steroidal anti-inflammatory drugs \[NSAIDs\]). All subjects provided their written informed consent before enrollment. The study protocol was approved by the ethics committee of Gihoku Kosei Hospital and performed in accordance with the Declaration of Helsinki.

Statistical analyses {#s4_2}
--------------------

The χ^2^ test or Student\'s *t*-test were used to compare the proportions of categorical variables between the diabetic and non-diabetic groups. The correlation between the individual factors (age, gender, BMI, FIT positivity, HbA1c values, complications, habits and current medications) and the prevalence of colorectal neoplasia (CRC and adenoma) was also evaluated by the Pearson χ^2^ test, Student\'s *t*-test, or Fisher\'s exact test. A univariate analysis was performed in type 2 DM patients to identify possible predictors of colorectal neoplasia, and a multivariate analysis was then carried out with the variables that were significant in the univariate analysis (*p* \< 0.05) and that had been reported to increase or decrease the risk of CRC.

All of the statistical analyses were performed using the JMP^®^ 11 software program (SAS Institute Inc., Cary, NC, USA). *P* values of \< 0.05 were considered to indicate statistical significance.
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